ArticleInvestigational new drugs2020

A first-in-human, phase 1, dose-escalation study of ABBV-176, an antibody-drug conjugate targeting the prolactin receptor, in patients with advanced solid tumors.

Charlotte Lemech et al.PubMed ↗Publisher ↗

No numbers read from the abstract.